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Endostatin: An Endogenous Inhibitor
of Angiogenesis and Tumor Growth
Michael S. O'Reilly,* Thomas Boehm,* Yuen Shing,* result of a net balance between these positive and nega-
tive regulators of neovascularization (Rastinejad et al.,Naomi Fukai,² George Vasios,§ William S. Lane,³
Evelyn Flynn,* James R. Birkhead,§ 1989; Good et al., 1990; O'Reilly et al., 1994; Parangi et
al., 1996). Several other endogenous inhibitors of angio-Bjorn R. Olsen,² and Judah Folkman*
*Department of Surgery genesis have been identified, although not all areassoci-
ated with the presence of a tumor. These include plateletChildren's Hospital, Boston
Departments of Surgery and Cellular Biology factor 4 (Maione et al., 1990; Gupta et al., 1995), inter-
feron-alpha, interferon-inducible protein 10 (AngiolilloHarvard Medical School
300 Longwood Avenue et al., 1995; Strieter et al., 1995), which is induced by
interleukin-12 and/or interferon-gamma (Voest et al.,Boston, Massachusetts 02115
²Department of Cell Biology 1995), gro-beta (Cao et al., 1995), and the 16 kDa
N-terminal fragment of prolactin (Clapp et al., 1993).Harvard Medical School
220 Longwood Avenue Prior to this report, however, the only known angiogen-
esis inhibitor that specifically inhibited endothelial cellBoston, Massachusetts 02115
³Harvard Microchemistry Facility proliferation was angiostatin (O'Reilly et al., 1994).
We previously reported that angiostatin, a 38 kDa spe-16 Divinity Avenue
Harvard University cific inhibitor of endothelial cell proliferation, is an inter-
nal fragment of plasminogen containing at least threeCambridge, Massachusetts 02138
§Osteoarthritis Sciences, Inc. of the kringles of plasminogen (O'Reilly et al., 1994). In
that report, angiostatin was isolated from a subcloneCambridge, Massachusetts 02139
of Lewis lung carcinoma in which the primary tumor
inhibited the growth of its metastases. Angiostatin, gen-
erated by the primary tumor, was shown to potently
Summary inhibit angiogenesis. In fact, systemic therapy with
angiostatin led to the maintenance of metastases in
We previously identified the angiogenesis inhibitor a microscopic dormant state defined by a balance of
angiostatin. Using a similar strategy, we have identi- apoptosis and proliferation of the tumor cells ( O'Reilly et
fied endostatin, an angiogenesis inhibitor produced al., 1994; Holmgren et al., 1995). We have subsequently
by hemangioendothelioma. Endostatin is a 20 kDa shown that angiostatin therapy can also inhibit the
C-terminal fragment of collagen XVIII. Endostatin spe- growth of three different types of murine primary tumors,
cifically inhibits endothelial proliferation and potently even if therapy is not initiated until tumors are 2% of
inhibits angiogenesis and tumor growth. By a novel body weight (O'Reilly et al., 1996). We have not found
method of sustained release, E. coli±derived endos- any tumors that become resistant to angiostatin and
tatin was administered as a nonrefolded suspen- have not observed any toxicity due to angiostatin at
sion. Primary tumors were regressed to dormant doses tested, i.e., up to 100 mg/kg. We have not tested
microscopic lesions. Immunohistochemistry revealed angiostatin above this dose. Recombinant fragments of
blocked angiogenesis accompanied by high prolifera- angiostatin have since been made that show inhibitory
tion balanced by apoptosis in tumor cells. There was activity in vitro (Cao et al., 1996). Recently, angiostatin
no toxicity. Together with angiostatin data, these find- has been shown to beproduced by the proteolytic cleav-
ings validate a strategy for identifying endogenous age of plasminogen by a serine protease from several
angiogenesis inhibitors, suggest a theme of fragments human prostate carcinoma cell lines (Gately et al., 1996).
of proteins as angiogenesis inhibitors, and demon- We now show that a similar rationale as was used for
strate dormancy therapy. the isolation of angiostatin has led to the isolation of
a novel 20 kDa angiogenesis inhibitor from a murine
hemangioendothelioma. We have named this inhibitoryIntroduction
protein endostatin. Endostatin is a specific inhibitor of
endothelial proliferation and is a potent angiogenesisSeveral lines of direct evidence show that angiogenesis
inhibitor. Systemic therapy with endostatin causes ais essential for the growth and persistence of solid tu-
nearly complete suppression of tumor-induced angio-mors and their metastases (Folkman, 1989; Hori et al.,
genesis, which results in a strong antitumor activity.1991; Kim et al., 1993; Millauer et al., 1994). To stimulate
angiogenesis, tumors upregulate the production of a
variety of angiogenic factors, including fibroblast growth Results
factors (aFGF and bFGF) (Kandel et al., 1991) and vascu-
lar endothelial cell growth factor/vascular permeability Identification of an Inhibitor of Capillary
Endothelial Cell Proliferation fromfactor (VEGF/VPF). Many malignant tumors, however,
also generate inhibitors of angiogenesis (Chen et al., Hemangioendothelioma Cells
A murine hemangioendothelioma cell line, EOMA1995), including angiostatin (O'Reilly et al., 1994; Gately
et al., 1996) and thrombospondin (Good et al., 1990). It (Obeso et al., 1990), was evaluated for evidence of the
production of inhibitors of endothelial cell proliferation.is becoming clear that the angiogenic phenotype is the
Cell
278
of reverse-phase HPLC with a C4 column. The inhibitory
activity was eluted from the C4 column with 40±45%
acetonitrile in 0.1% trifluoroacetic acid. After the final
C4 column, the inhibitory activity was associated with
a protein of molecular mass 20 kDa (reduced) or 18
kDa (nonreduced), by SDS-PAGE, purified to apparent
homogeneity (Figure 2A). In a representative purifica-
tion, 10 l of conditioned media containing 500 mg of
protein was used to purify 2 mg of purified inhibitor. The
inhibitory activity was purified by 5000-fold with a 2%
recovery of activity.
To characterize further the 20 kDa inhibitor, we tested
it on several cell lines of endothelial and nonendothelial
origin. Only endothelial cells were significantly inhibited
(Figure 3). The dose-dependent inhibition was first ob-
Figure 1. Inhibition of Capillary Endothelial Cell Proliferation by served at doses of 100 ng/ml with maximal inhibition
Conditioned Media from EOMA Cells
observed at doses of 600 ng/ml or greater (Figure 3A).No
Conditioned media collected from EOMA cells or base media was significant inhibition was seen for cells of nonendothelial
applied to bovine capillary endothelial cells with 1 ng/ml bFGF in a
origin (Figure 3B) at doses 1 log-fold higher than those72 hr proliferation assay. Endothelial cell proliferation was inhib-
used to inhibit capillary endothelial cells (data notited by the EOMA conditioned media. Each bar represents the
mean 6 SEM. shown). Notably, the proliferation of the EOMA cell line
was not inhibited by the purified 20 kDa protein.
Many of the known endogenous inhibitors of angiogen-
Microsequence Analysis of the 20 kDa Proteinesis inhibit the in vitro proliferation of endothelial cells.
Reveals Identity to a FragmentConditioned media from EOMA cells was applied to
of Collagen XVIIIbovine capillary endothelial cells, stimulated with bFGF,
Microsequence analysis of the inhibitor revealed identityin a 72 hr proliferation assay. The conditioned media
to a C-terminal fragment of collagen XVIII. The molecularreversibly inhibited theproliferation of capillary endothe-
cloning and sequence of collagen XVIII was first de-lial cells as compared with controls. The pattern of inhi-
scribed by Olsen and his coworkers and by Rehn andbition was consistent with the presence of inhibitory
Pihlajaniemi (Oh et al., 1994; Rehn and Pihlajaniemi,and stimulatory activity of endothelial cell proliferation
1994). Collagen XVIII is a novel collagen that consists(Figure 1).
of an N-terminal region with three splice variants (Mura-
gaki et al., 1995; Rehn and Pihlajaniemi, 1995), a seriesThe Inhibitory Activity of Endothelial Cell
of collagen-like domains with interruptions, and a 35Proliferation Is Not Due to Angiostatin
kDa C-terminal noncollagenous (NC1) domain. An 18To determine whether or not the inhibitor of capillary
amino acid N-terminal microsequence analysis of theendothelial cell proliferation produced by the EOMA
purified inhibitor of endothelial cell proliferationconfirmscells was angiostatin, pooled conditioned media was
that it is identical to a C-terminal fragment of this NC1applied to lysine Sepharose. Lysine Sepharose binds
domain (Figure 2B). We have named this inhibitory frag-angiostatin and has been used for its purification
ment endostatin.(O'Reilly etal., 1996). The endothelial cell inhibitory activ-
ity was found only in the flow-through fraction and not
in the bound fractions (data not shown). The lack of Recombinant Endostatin Inhibits Endothelial
Cell Proliferation In Vitrobinding of the inhibitory activity to lysine Sepharose
suggested that the inhibitor of endothelial cell prolifera- We produced recombinant mouse endostatin in bacu-
lovirus and E. coli expression systems. Using sequentialtion was not angiostatin.
heparin Sepharose chromatography, recombinant en-
dostatin was purified to apparent homogeneity from in-Purification of a 20 kDa Protein from the
Conditioned Media of EOMA Cells That sect cell media. Ni21-NTA-agarose was used to purify
the E. coli±derived endostatin. SDS-PAGE revealed aSpecifically Inhibits Endothelial
Cell Proliferation discrete band of 20 or 22 kDa (reduced) purified to ap-
parent homogeneity for baculovirus and E. coli±derivedBecause several angiogenic inhibitors have an affinity
for heparin, we applied the flow-through from the lysine recombinant endostatins, respectively (data not shown).
Both were dialyzed against PBS prior to use. After dial-Sepharose column to a heparin Sepharose column. The
inhibitory activity bound heparin with relatively high af- ysis, the material from the E. coli system precipitated
and the insoluble purified protein was delivered as afinity and was eluted with 0.6±0.8 M NaCl in 10 mM Tris
(pH 7.4.) Of interest was a stimulatory activity in the suspension for in vivo studies. Recombinant endostatin
(baculovirus) specifically inhibited the proliferation ofconditioned media that eluted from the heparin column
with 0.4 M NaCl. To purify further the inhibitory activity, bovine capillary endothelial cells in a dose-dependent
fashion (data not shown). The inhibition was similar tothe sample was concentrated and applied to a gel filtra-
tion (Bio-Rad Bio-Gel P-100 fine gel or Pharmacia Seph- that seen for native endostatin (see Figure 3A) with maxi-
mal inhibition observed at doses above 600 ng/ml. Noacryl S-200HR gel) column followed by several cycles
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Figure 2. Purification of an Inhibitor of Endo-
thelial Proliferation from EOMA-Conditioned
Media
(A) SDS-PAGE. An aliquot (z100 ng) of the
purified inhibitor of endothelial cell prolifera-
tion was analyzed by electrophoresis in a
10%±18% polyacrylamide gel. Inhibitory ac-
tivity was associated with a protein of appar-
ent Mr 20,000 (silver stain). Molecular mass
markers (3 1023) are as indicated.
(B) Amino acid sequence. The N-terminal se-
quence of the purified inhibitor of endothelial
cell proliferation (endostatin) is noted in rela-
tion to a schematic of collagen XVIII. N-termi-
nal sequence reveals identity of the inhibitor to a 20 kDa C-terminal fragment (solid shading) of collagen XVIII. We have named this inhibitor
endostatin. The open boxes represent the collagenous domains of collagen XVIII.
significant inhibition of proliferation of cells of nonendo- within 24 hr and gave a maximal antiangiogenic effect
within a period of 48 hr. There was no evidence of toxicitythelial origin or of EOMA cells was observed (Figure 3B)
when endostatin was tested at doses up to 1 log-fold in any of the chick embryos tested.
higher than those used to inhibit endothelial cells. The
precipitated (nonrefolded) material was not testable in Recombinant Endostatin Inhibits
the Growth of Metastasesvitro because of its insolubility in culture media. How-
ever, a small percentage of the material spontaneously Because tumor growth is angiogenesis dependent, we
treated Lewis lung carcinoma metastases systemicallysolubilized in the PBS during dialysis. In the endothelial
cell assays, this material inhibited at concentrations with recombinant mouse endostatin expressed in the
baculovirus system. The growth of metastases was al-comparable to both the native and baculovirus-derived
endostatin. Furthermore, when the recombinant endos- most completely suppressed by the systemic adminis-
tration of endostatin at a dose of 0.3 mg/kg/day giventatin (E. coli) was refolded, it was soluble and inhibited
endothelial proliferation (data not shown). The refolding subcutaneously (7 6 3 metastases per mouse, n 5 4).
In contrast, in mice treated with saline after removal ofprocess, however, resulted in a loss of greater than 99%
of the protein. It was therefore not feasible to test this a Lewis lung carcinoma primary tumor, lung metastases
grew rapidly (77 6 7 metastases per mouse, p < 0.001).material in the in vivo assays.
Lung weight, which reflects tumor burden, was 240 6
25 mg in the endostatin-treated mice versus 760 6 30Recombinant Endostatin Inhibits Angiogenesis
To test for the ability of recombinant mouse endostatin to mg in the control mice (p < 0.001). Furthermore, there
was no weight loss or evidence of toxicity in any of theinhibit in vivoangiogenesis,we used the chick chorioallan-
toic membrane (CAM) assay (Folkman, 1985; Nguyen et mice treated with endostatin.
al., 1994). At doses of 10±20 mg/disc, there was potent
inhibition of angiogenesis for the E. coli± and baculovi- Recombinant Mouse Endostatin Inhibits
the Growth of Primary Tumorsrus-derived endostatins in all of the tested CAMs (n 5
5/group). Because of the low yield of E. coli±derived The yield of endostatin from the baculovirus system was
lower than that of the E. coli system, i.e., 1±2 mg/l versusendostatin protein recovered after refolding, we used
the nonrefolded purified protein for the in vivo studies. 30±40 mg/l. We therefore used E. coli±derived endo-
statin to study the effect of endostatin therapy on pri-The E. coli±derived endostatin precipitate was observed
to dissolve gradually from the discs over five days and mary tumors. We produced recombinant mouse endos-
tatin from E. coli in sufficient quantity to treat severalproduced a sustained antiangiogenic effect. In contrast,
the soluble baculovirus-derived endostatin dissolved different types of primary tumors growing in syngeneic
Figure 3. Specific Inhibition of Capillary En-
dothelial Cell Proliferation by Native and Re-
combinant Endostatin
(A) Endostatin purified from EOMA-condi-
tioned media was applied to bovine capillary
endothelial cells with 1 ng/ml bFGF in a 72
hr proliferation assay. Endostatin inhibited
endothelial cell proliferation in a dose-depen-
dent fashion. Each bar represents the mean 6
SEM.
(B) Recombinant or native endostatin was ap-
plied to a wide variety of nonendothelial types
in a 72 hr proliferation assay. No significant
inhibition of proliferation was seen at doses
up to 1 log-fold higher than those required to
inhibit endothelial cell proliferation.
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Figure 4. Dose-Dependent Inhibition of Lewis Lung Carcinoma Pri-
mary Tumors by Recombinant Endostatin
Mice were implanted with Lewis lung carcinomas and systemic
therapy with recombinant mouse endostatin (E. coli) was begun
when tumors were approximately 200 mm3. Mice were treated with
doses of 2.5, 10, and 20 mg/kg injected once daily. A dose-depen-
dent inhibition of tumor growth was observed. Representative data
for saline treated mice are shown (n 5 5). Each point represents
mean 6 SEM for six mice (20 mg/kg) or four mice (2.5 and10 mg/kg).
mice. Lewis lung carcinoma, T241 fibrosarcoma, EOMA
hemangioendothelioma, and B16F10 melanoma were
implanted into mice and grown to at least 100±200 mm3.
When purified nonrefolded endostatin was dialyzed
against PBS, it precipitated. The precipitated protein
was resuspended and the suspension was administered
to the mice via subcutaneous injection. The injected
precipitate formed a pellet at the injection site. Mice
were observed several times daily and the pellet was
noted to resorb slowly over a 24±48 hr period. These
observations suggest that the injected nonrefolded en-
dostatin protein acts as a subcutaneous depot with re-
lease over a 24±48 hr period.
The growth of Lewis lung primary tumors was potently
suppressed by systemic endostatin therapy (Figures 4
and 5). Increasing doses of endostatin were associated
with improved efficacy (Figure 4). Tumor growth was
inhibited by 53% at a dose of 2.5 mg/kg as compared
Figure 5. Systemic Therapy with Recombinant Endostatin Re-to control mice treated with vehicle alone (Figure 4). At
gresses Lewis Lung Carcinoma Primary Tumors
10 mg/kg, tumor growth was inhibited by 97% (Figure
The subcutaneous dorsa of mice were implanted with Lewis lung4). At 20 mg/kg given once daily, in several separate
carcinomas.
experiments, there was an almost complete regression (A) Results of systemic therapy with recombinant mouse endostatin
of established primary tumors (>99% inhibition, p < (20 mg/kg/day) initiated when tumors were z200 mm3 (1% of body
0.001) (Figures 4 and 5). Immunohistochemical analysis weight). Tumors in mice treated with endostatin rapidly regressed
and were inhibited by >99% relative to saline-treated controls. Each(Figure 6) of the residual small tumors (Figure 5C)
point represents mean 6 SEM for five mice. The experiment wasshowed a potent inhibition of angiogenesis in the endo-
repeated with comparable results.statin-treated tumors. Furthermore, the proliferative in-
(B) Representative treated and control mice after 11 days of sys-
dex of tumors in the endostatin- and saline-treated mice temic therapy with endostatin. Saline-treated mice (right) had rapidly
was at the same high level in both groups while the growing red tumors with ulcerated surfaces. Endostatin- treated
apoptotic index increased 7-fold after endostatin ther- mice (left) had small pale residual tumors (arrow).
(C) Residual disease in endostatin treated mice. Three of the fiveapy (Figure 6). Thus, endostatin therapy results in a
endostatin treated mice were sacrificed after 16 days of therapy.similar pattern of tumor dormancy to the one previously
Autopsy revealed small white residual tumors at the site of thedescribed for angiostatin (Holmgren et al., 1995; O'Reilly
original primary implantation (arrows).
et al., 1996). Furthermore, there was no evidence of
drug-related toxicity in any of the mice.
In a separate series of experiments, syngeneic mice in any of the treated mice (Figure 7). Continued endo-
statin therapy maintained the tumors in a state of dor-implanted with several other malignant tumors, includ-
ing B16F10 melanoma, T241 fibrosarcoma, and EOMA mancy for as long as it was administered. These data
strongly suggest that the antiangiogenic effect of endo-hemangioendothelioma were treated with the recombi-
nant endostatin precipitate. All of the tumors tested rap- statin can be used to target a wide variety of primary
malignancies.idly regressed and there was no evidence of any toxicity
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Figure 6. Endostatin Results in an Inhibition
of Angiogenesis and an Increase in Apoptosis
of Lewis Lung Carcinoma Primary Tumors
Histological sections of tumors from saline-
versus endostatin- treated Lewis lung carci-
nomas were analyzed for proliferation (PCNA),
apoptosis (TUNEL), and angiogenesis (vWF).
There was no significant difference in the pro-
liferative index of tumor cells (A) in treated
versus untreated tumors. In contrast, the
apoptotic index of the tumor cells (B) in-
creased 7-fold (p < 0.001) in the endostatin-
treated mice. Vessel density (C) was deter-
mined by counting the number of capillary
blood vessels per highpower field (HPF) in sections stained with antibodies against vWF. Angiogenesis was almost completely suppressed
in the residual microscopic tumors of the endostatin-treated mice (p < 0.001).
After discontinuation of endostatin therapy, a tumor tag, which was expressed, purified and administered in
a comparable fashion to the N-terminal-tagged productrecurred at the primary site within 5±14 days, became
described above did not inhibit angiogenesis in the CAMvascularized, and eventually killed the mice (data not
assay and had no effect on the growth of Lewis lungshown). Notably, we found that E. coli±derived recombi-
carcinomas (data not shown). These data argue stronglynant mouse endostatin with a C-terminal polyhistidine
that the antitumor and antiangiogenic activity of recom-
binant endostatin are due to the specific structure of
endostatin and not to a contaminant in the sample.
Discussion
These results show that a murine hemangioendotheli-
oma produces a novel and specific 20 kDa inhibitor
of endothelial cell proliferation in vitro that is a potent
inhibitor of angiogenesis and tumor growth in vivo. The
N-terminal sequence of this inhibitor, endostatin, is iden-
tical to a C-terminal fragment of collagen XVIII. Systemic
administration of recombinant endostatinpotently inhib-
its angiogenesis, maintains metastases at a microscopic
size, and regresses primary tumors to less than 1 mm3,
a reduction of over 150-fold. For as long as mice are
treated (i.e., in experiments that last 16±25 days), there
is no regrowthof tumors, no evidence of drug resistance,
and no toxicity.
Collagen XVIII is a recently reported member of a
family of collagen-like proteins (Oh et al., 1994; Rehn
and Pihlajaniemi, 1994), referred to as the multiplexins,
and is localized mainly in a perivascular position around
blood vessels (Muragaki et al., 1995). It is tempting to
speculate that the presence of a powerful endothelial
inhibitor within a protein localized to blood vessels may
provide a regulatory mechanism for vessel growth. Mice
that are homozygous for collagen XVIII knockout alleles
develop normally, however, with no evidence of abnor-
mal vascular morphogenesis (N. F. et al., unpublished
data). Thus, collagen XVIII may not represent a rate-
limiting negative regulator for vessel growth during em-
bryonic development but may represent a source of
regulatory activity released by proteolytic cleavage of
the intact molecule under conditions of induced angio-
genesis. Therefore, it may become as important to eluci-
Figure 7. Systemic Therapy with Recombinant Endostatin Re- date the role of proteases in the suppression of angio-
gresses a Wide Variety of Primary Malignancies genesis as it has been to find those proteases that
The subcutaneous dorsa of mice were implanted with Lewis lung participate in its initiation (Gross et al., 1983).
carcinomas and systemic therapy with recombinant mouse endo- We found endostatin by the same strategy that we
statin (20 mg/kg/day) was begun when tumors were z200 mm3 (1%
had employed to find angiostatin (O'Reilly et al., 1994),of body weight). Tumors in the mice treated with endostatin rapidly
i.e., isolation from a tumor. While it appears to be coun-regressed and were inhibited by >99% relative to saline-treated
terintuitive that tumors should be a source of angiogen-controls (n 5 5). Each point represents mean 6 SEM for ten (T241),
four (B16F10), or three (EOMA) mice. esis inhibitors, the results reported here seem to validate
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the approach. Furthermore, several different human tu- than in untreated mice. This pattern is similar to that
observed with angiostatin therapy of primary tumors ormors growing in immunocompromised mice have been
shown to be associated with the presence of circulating their metastases (O'Reilly et al., 1994, 1996; Holmgren
et al., 1995), and suggests that suppression of the endo-inhibitors of angiogenesis (Chen et al., 1995).
This leads to the question of why angiogenesis inhibi- thelial cell population may act to withdraw paracrine
factors from the tumor cell population.tors should be present in tumors that are angiogenic.
One possibility is that an inhibitor could be ªleft-overº The fact that a specific inhibitor of endothelial cell
proliferation can regress a tumor to a microscopic sizeafter down-regulation of its production by a tumor cell
undergoing the switch to the angiogenic phenotype. and hold it in a dormant state, despite the fact that the
tumor cells are refractory to the inhibitor from the outset,This appears to be the case for thrombospondin pro-
duced by Li-Fraumeni cells in which the second allele indicates that the endothelial population can exert pow-
erful growth regulatory control over the tumor cells. Thefor p53 is mutated or deleted (Dameron et al., 1994). A
second possibility is that the proteolytic activity that tumor suppressive effect brought about by endostatin
demonstrates, in an even more compelling way thanaccompanies tumor growth, and which is an important
component of capillary blood vessel growth, may also angiostatin (O'Reilly et al., 1996), that dormancy therapy
is at least feasible in experimental animals. It remainsmobilize circulating angiogenesis inhibitors from precur-
sor proteins that are not inhibitory themselves. Angio- to be seen whether this approach, based on prolonged
and potent antiangiogenic therapy can be translated tostatin, for example, inhibits angiogenesis while plas-
minogen does not (O'Reilly et al., 1994, 1996). For cancer patients. The results with endostatin support our
previous proposal (Folkman, 1996) that for therapeuticendostatin, a similar pattern is revealed. Although it is
not practical to produce full length collagen XVIII, frag- purposes it is fruitful to think about a tumor in terms of
two distinct cell populations, a tumor cell populationments of its C-terminal domain that are longer than en-
dostatin do not inhibit endothelial cell proliferation (data and an endothelial cell population, each of which can
stimulate growth of the other. Growth of each cell popu-not shown). Furthermore, the 16 kDa N-terminal frag-
ment of prolactin (Clapp et al., 1993), an internal frag- lation may be optimally inhibited by agents that selec-
tively or specifically target that cell type, i.e., cytotoxicment of platelet factor 4 (Maione et al., 1990; Gupta
et al., 1995), synthetic fragments of murine epidermal chemotherapy and antiangiogenic therapy. Further-
more, combined treatment of both cell populations maygrowth factor (Nelson et al., 1995), fragments of laminin
(Grant et al., 1989; Sakamato et al., 1991), and peptides be better than treatment of either compartment alone
(Teicher et al., 1994).derived from thrombospondin (Good et al., 1990; Tolsma
et al., 1993) all inhibit endothelial cell proliferation. The The systemic administration of precipitated and non-
refolded recombinant endostatin from E. coli permittedproteolytic cleavage of platelet factor 4, which is itself
an endothelial cell inhibitor, with plasmin increases its sustained release of the purified protein from a subcuta-
neous depot. It should be noted that the nonrefoldedinhibitory activity by more than 50-fold (Gupta et al.,
1995). Also, fragments produced in vitro, such as a 29 form precipitated in the in vitro endothelial cell assay,
and thus could not be tested for antiproliferative activity.kDa plasmin-derived fragment of fibronectin (Homand-
berg et al., 1985) and a fragment of SPARC (Sage et al., When endostatin was refolded by standard methods, it
became soluble in tissue culture media and potently1995), can inhibit the proliferation of endothelial cells.
Thus, a theme appears to be emerging of endogenous inhibited endothelial cell proliferation. There was signifi-
cant loss of protein, however, during the refolding pro-inhibitors of angiogenesis arising from larger proteins
with distinct and varied functions. If the responsible cess. We are unaware of any precedent for the use of
an injected depot of nonrefolded recombinant proteinproteases and the common cleavage sites can be eluci-
dated, a new general mechanism of growth regulation as a sustained-release method inanimals. Nevertheless,
endostatingradually resorbed in vivoand proved tohavein the vascular system may be revealed, not unlike the
cascade of proteolytic events in the coagulation system. potent antiangiogenic activity that resulted in prolonged
antitumor activity. Therefore, these data suggest a novelHistology of tumors that regressed with endostatin
therapy showed perivascular cuffing of tumor cells sur- general method for the controlled release of recombi-
nant proteins. Based on this same rationale, we haverounding one or more microvessels in which angiogen-
esis was blocked. Tumor cells displayed high prolifera- delivered nonrefolded recombinant angiostatin from E.
tion balanced by high apoptosis, with no net gain in coli with similar success.
tumor size. These data are consistent with a model of Finally, the discovery of endostatin, its ability to inhibit
a new type of tumor dormancy that we previously pro- specifically endothelial proliferation, and its potent anti-
posed (Holmgren et al., 1995). Furthermore, endostatin tumor effect provide the most compelling proofof princi-
inhibited proliferation of endothelial cells in vitro but had ple to date that tumors are angiogenesis dependent.
no effect on Lewis lung carcinoma cells or other cell
types including smooth muscle, epithelium, fibroblasts, Experimental Procedures
and the EOMA cell line from which it was purified.
Conditioned Media CollectionThese results are reflected in the histology of treated
The murine hemangioendothelioma cell line EOMA was obtainedtumors, where only angiogenesis appears tobe inhibited
from Cindy Meinenger and Robert Auerbach. The cells were main-
and not Lewis lung carcinoma proliferation. In fact, the tained in DMEM supplemented with 10% bovine calf serum (BCS)
high rate of tumor cell proliferation was not different from and 1% glutamine-penicillin-streptomycin (GPS) in a 378C and 10%
tumor cell proliferation in untreated mice. The apoptosis CO2 incubator. To produce conditioned media, 150 ml of DMEM
with 3% BCS and 1% GPS was added to near confluent EOMA cellsrate of tumor cells in treated mice was 7-fold higher
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in 900 cm2 roller bottles. After 72 hr, at 378C and 5% CO2, media LLC cells, and BCS was used for the other cell types. A cell suspen-
sion (20,000 cells/ml for SMC, RPE, MLE; 15,000 cells/ml for 3T3;was collected, filtered (0.45 mm), and stored at 48C.
10,000 cells/ml for LLC, EOMA) was made with DMEM 1 10% bovine
serum 1 1% GPS, plated onto 24-well culture plates (0.5 ml/well),Purification of Inhibitory Activity from Conditioned Media
and incubated (378C, 10% CO2) for 24 hr. The media was replacedLysine Sepharose, heparin Sepharose, Sephacryl S-200 HR gel
with 0.5 ml of DMEM 1 5% bovine serum 1 1% GPS and the(Pharmacia, Uppsala, Sweden), Bio-Gel P-100 fine polyacrylamide
test sample applied. After 72 hr, cells were dispersed in trypsin,gel (Bio-Rad Laboratories, Richmond, CA), and a SynChropak RP-4
resuspended in Hematall (Fisher Scientific, Pittsburgh, PA), and(100 3 4.6mm) C4 reverse-phase column (Synchrom, Inc., Lafayette,
counted by Coulter counter.IN) were prepared according to the manufacturers' recommenda-
tions. A heparin Sepharose column (50 3 2.5 cm) was equilibrated
Chick Chorioallantoic Membrane Assaywith 50 mM NaCl 10 mM Tris-HCl (pH 7.4). Pooled conditioned media
Three-day-old fertilized white Leghorn eggs (Spafas, Norwich, CT)was applied and the column was washed with the equilibration
were cracked, and embryos with intact yolks were placed in 100 3buffer. The column was eluted with a continuous gradient of 50
20 mm petri dishes (Folkman, 1985). After three days of incubationmM±2 M NaCl in 10 mM Tris-HCl (pH 7.4) (200 ml total volume)
(378C and 3% CO2), a methylcellulose (Fisher Scientific, Fair Lawn,followed by 100 ml of 2 M NaCl in 10 mM Tris-HCl (pH 7.4). Fractions
NJ) disc containing endostatin was applied to the CAM of individualwere collected and an aliquot of each was applied to capillary endo-
embryos. The discs were made by desiccation of endostatin in 10thelial cells in a 72 hr proliferation assay. Fractions that inhibited
ml of 0.45% methylcellulose (in H2O) on teflon rods. After 48 hrproliferation were dialyzed (Molecular Weight Cut-Off (MWCO) 5
of incubation, embryos and CAMs were observed by means of a6000±8000) against PBS and concentrated using a 4000 MWCO
stereomicroscope. Embryos were observed daily until there was noNanospin concentrator (Gelman Sciences, Ann Arbor, MI).
evidence of inhibitory zones.A Bio-Gel P-100 column or a Sephacryl S-200 HR column (75 3
1.5 cm) was equilibrated with PBS. The sample from heparin Sepha-
Animal Studiesrose chromatography was applied and the column was eluted with
Animal work was carried out in the animal facility of Children'sPBS. Fractions were collected and an aliquot of each was applied
Hospital in accordance with institutional guidelines. Male 6- toto endothelial cells. Fractions that inhibited endothelial proliferation
8-week-old C57Bl6/J or 129/J mice (Jackson Labs, Bar Harbor, ME)were concentrated and dialyzed as above.
were used. Mice were acclimated, caged in groups of four or less,A SynChropak RP-4 (100 3 4.6 mm) column was equilibrated with
and their backs shaved. All mice were fed a diet of animal chowH2O/0.1% trifluoroacetic acid (TFA). HPLC-grade reagents (Pierce,
and water ad libitum. Animals were anesthetized in a methoxyfluraneRockford, IL) were used. The sample from gel filtration chromatogra-
(Pittman-Moore Inc., Mundelein, IL) chamber prior to all proceduresphy was applied, the column was eluted with a gradient of acetoni-
and were observed until fully recovered. Animals were sacrificed bytrile in 0.1% TFA at 0.5 ml/min, and fractions were collected. An
a lethal dose of methoxyflurane.aliquot of each was evaporated by vacuum centrifugation, resus-
pended in PBS, and applied to capillary endothelial cells. Inhibitory
Mouse Metastasis Modelactivity was further purified to apparent homogeneity by at least
Animals with Lewis lung carcinomas of 600±1200 mm3 tumors weretwo subsequent cycles on the SynChropak C4 column.
sacrificed, and the skin overlying the tumor was cleaned with beta-
dine and ethanol. In a laminar flow hood, tumor tissue was excisedProtein Microsequencing
under aseptic conditions. A suspension of tumor cells in 0.9% nor-The 20 kDa inhibitor of capillary endothelial cell proliferation was
mal saline was made by passage of viable tumor tissue through apurified to homogeneity from several batches of conditioned media,
sieve and a series of sequentially smaller hypodermic needles ofresolved by SDS-PAGE, electroblotted onto PVDF (Bio-Rad, Rich-
diameter 22- to 30-gauge. The final concentration was adjusted tomond, CA), detected by Ponceau S stain, and excised from the
1 3 107 cells/ml and the suspension was placed on ice. After themembrane. N-terminal sequence was determined by automated Ed-
site was cleaned with ethanol, the subcutaneous dorsa of mice inman degradation on a PE/ABD Model 470A protein sequencer (Fos-
the proximal midline were injected with 1 3 106 cells in 0.1 ml ofter City,CA) operated with gas-phase deliveryof trifluoroacetic acid.
saline.Sequence library searches and alignments were performed
When tumors were 1500 mm3 in size, approximately 14 days afteragainst combined GenBank, Brookhaven Protein, SWISS-PROT,
implant, the mice underwent surgical removal of the tumor. Theand PIR databases. Searches were performed at the NationalCenter
incision was closed with simple interrupted sutures. From the dayfor Biotechnology Information through the use of the BLAST network
of operation, mice received daily intraperitoneal injections of recom-service.
binant (baculovirus) mouse endostatin or saline. Mice received 0.3
mg/kg/day of endostatin once daily via subcutaneous injection.
Bovine Capillary Endothelial Cell Proliferation Assay When the control mice became sick from metastatic disease, all
Bovine capillary endothelial cells were obtained and grown as pre- mice were sacrificed and autopsied. Lung surface metastases were
viously described (Folkman et al., 1979). For the proliferation assay, counted by means of a stereomicroscope at 43 magnification.
cells were washed with PBS and dispersed in a 0.05% trypsin solu-
tion. A cell suspension (25,000 cells/ml) was made with DMEM 1 Treatment of Murine Primary Malignant Tumors
10% BCS 1 1% GPS, plated onto gelatinized 24-well culture plates C57Bl6/J mice were implanted with Lewis lung carcinomas, T241
(0.5 ml/well), and incubated (378C, 10% CO2) for 24 hr. The media fibrosarcomas, or B16F10 melanomas using the techniques de-
was replaced with 0.25 ml of DMEM 1 5% BCS 1 1% GPS and the scribed above. For the EOMA implantations, EOMA cells, grown in
test sample applied. After 20 min of incubation, media and bFGF culture as above, were washed with PBS, dispersed in a 0.05%
were added to obtain a final volume of 0.5 ml of DMEM 1 5% BCS 1 solution of trypsin, and resuspended. After centrifugation (4000 rpm
1% GPS 1 1 ng/ml bFGF. After 72 hr, cells were dispersed in trypsin, for 10 min at 88C), the cell pellet was resuspended in PBS and the
resuspended in Hematall (Fisher Scientific, Pittsburgh, PA), and concentration was adjusted to 2.5 3 106 cells/ml. 129/J mice were
counted by Coulter counter. then injected with 0.1 ml of the suspension as above. Tumors were
measured with a dial-caliper, volumes were determined using the
formula width2 3 length 3 0.52, and the ratio of treated to controlNonendothelial Cell Proliferation Assays
Bovine aortic smooth muscle (SMC), bovine retinal pigment epithe- tumor volume (T/C) was determined for the last time point. After
tumor volume was at least 100±200 mm3 (0.5±1% of body weight),lial (RPE), mink lung epithelial (MLE), Lewis lung carcinoma (LLC),
and EOMA cells and 3T3 fibroblasts were maintained in a 10% CO2 which occurred within 3±11 days, mice were randomized into two
groups. One group received recombinant mouse endostatin (E. coli)and 378C incubator. For the proliferation assays, cells were washed
with PBS and were dispersed in a 0.05% trypsin solution. Optimal as a suspension in PBS injected subcutaneously at a site distant
from the tumor once daily. The other group received comparableconditions for the cell proliferation assays were established for each
cell type. Fetal calf serum (FCS) was used for the RPE, MLE, and injections of the vehicle alone. The experiments were terminated
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and mice were sacrificed and autopsied when the control mice was resuspended in the PBS, the protein concentration was ad-
justed to 2±4 mg/ml, and the endostatin was stored at 2208C untilbegan to die.
use. For the mouse studies, endostatin was delivered as a suspen-
sion in PBS. The suspension was thawed to 48C, vortexed, andExpression and Purification of Recombinant Mouse
resuspended through a 26-gauge needle. The subcutaneous dorsaEndostatin from Baculovirus
of mice were slowly injected via a 30-gauge needle with the endo-Recombinant mouse endostatin was expressed using the BacPAK
statin suspension. The concentration of the endostatinwas adjustedbaculovirus expression system (CLONTECH Laboratories) following
with PBS so that each mouse would receive 0.2 ml per 20 g of bodythe manufacturer's protocol. In brief, a cDNA fragment encoding the
weight. For the chick chorioallantoic assay, endostatin was furthersignal sequence and C-terminal part (endostatin region) of mouse
dialyzed against water and then evaporated by vacuum centrifu-collagen XVIII was inserted into the pBacPAK8 transfer vector. Bac-
gation.PAK6 viral DNA (expression vector) and plasmid DNA of the pBac-
PAK8-endostatin clone (modified transfer vector) were then cotrans-
fected into insect Sf21 cells. The BacPAK6 was first digested with Immunohistochemistry
BSU36 enzyme to make it incompetent for independent replication. Tumor tissue was fixed for 4 hr in Carnoy's fixative and transferred
Media containing expressed mouse endostatin was collected and to 100% ethanol. Tissues were embedded in paraffin according to
applied to a 1.5 3 40 cm heparin Sepharose column that had been standard histological procedures. PCNA and von Willebrand factor
equilibrated with 50 mM NaCl 10 mM Tris (pH 7.4). The column was (vWF) staining were performed as previously described (Holmgren
washed with the equilibration buffer and was then eluted sequen- et al., 1995). In brief, sections were pretreated with Proteinase K
tially with 0.2 M NaCl, 0.4 M NaCl, 0.6 M NaCl, and 1 M NaCl in 10 (vWF) or 10 mM citrate buffer (pH 6.0) (PCNA) and incubated with
mM Tris (pH 7.4). All chromatography was performed at 48C. The rabbit antiserum against human vWF (Dako) or with PC10 mono-
0.6 M NaCl eluant (which inhibited bovine capillary endothelial cells clonal antibody against PCNA (Signet). TdT labeling of fragmented
in a 72 hr proliferation assay) was dialyzed (MWCO 5 6000±8000) DNA (TUNEL) was performed according to the method of Gavrieli
against PBS and then reapplied to the heparin Sepharose column. et al. (1992). The proliferative index (PCNA) and the apoptotic index
The column was eluted with a gradient of 50 mM NaCl±1.2 M NaCl (TUNEL) were estimated by the percentage of cells scored under a
in 10 mM Tris (pH 7.4). An aliquot of each fraction was applied to light microscope at 200-fold magnification.
bovine capillary endothelial cells as above, and fractions that inhib-
ited proliferation were pooled, dialyzed against PBS, and concen- Acknowledgments
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